DOI: 10.1158/1078-0432.ccr-07-5136. Targeting the MDM2-p53 Interaction for Cancer Therapy

Targeting the MDM2-p53 Interaction for Cancer Therapy
10.1158/1078-0432.ccr-07-5136
Crossref journal-article
American Association for Cancer Research (AACR)
Clinical Cancer Research (1086)
Abstract
Abstract p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target because it can be functionally activated to eradicate tumors. The gene encoding p53 protein is mutated or deleted in half of human cancers, which inactivates its tumor suppressor activity. In the remaining cancers with wild-type p53 status, its function is effectively inhibited through direct interaction with the human murine double minute 2 (MDM2) oncoprotein. Blocking the MDM2-p53 interaction to reactivate the p53 function is a promising cancer therapeutic strategy. This review will highlight the advances in the design and development of small-molecule inhibitors of the MDM2-p53 interaction as a cancer therapeutic approach.
Bibliography
Shangary, S., & Wang, S. (2008). Targeting the MDM2-p53 Interaction for Cancer Therapy. Clinical Cancer Research, 14(17), 5318â5324.
Authors 2
Sanjeev Shangary (first)
Shaomeng Wang (additional)
References 68 Referenced 274
Dates
Type	When
Created	16 years, 11 months ago (Sept. 2, 2008, 10:59 a.m.)
Deposited	3 years, 2 months ago (June 10, 2022, 11:08 p.m.)
Indexed	2 weeks, 1 day ago (Aug. 6, 2025, 9:45 a.m.)
Issued	16 years, 11 months ago (Sept. 1, 2008)
Published	16 years, 11 months ago (Sept. 1, 2008)
Published Online	16 years, 11 months ago (Sept. 2, 2008)
Published Print	16 years, 11 months ago (Sept. 1, 2008)
Funders 0
None
BibTeX
@article{Shangary_2008, title={Targeting the MDM2-p53 Interaction for Cancer Therapy}, volume={14}, ISSN={1557-3265}, url={http://dx.doi.org/10.1158/1078-0432.ccr-07-5136}, DOI={10.1158/1078-0432.ccr-07-5136}, number={17}, journal={Clinical Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={Shangary, Sanjeev and Wang, Shaomeng}, year={2008}, month=sep, pages={5318–5324} }
JSON
{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        6
      ]
    ],
    "date-time": "2025-08-06T13:45:59Z",
    "timestamp": 1754487959285
  },
  "reference-count": 68,
  "publisher": "American Association for Cancer Research (AACR)",
  "issue": "17",
  "content-domain": {
    "domain": [
      "aacrjournals.org"
    ],
    "crossmark-restriction": true
  },
  "published-print": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  },
  "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target because it can be functionally activated to eradicate tumors. The gene encoding p53 protein is mutated or deleted in half of human cancers, which inactivates its tumor suppressor activity. In the remaining cancers with wild-type p53 status, its function is effectively inhibited through direct interaction with the human murine double minute 2 (MDM2) oncoprotein. Blocking the MDM2-p53 interaction to reactivate the p53 function is a promising cancer therapeutic strategy. This review will highlight the advances in the design and development of small-molecule inhibitors of the MDM2-p53 interaction as a cancer therapeutic approach.</jats:p>",
  "DOI": "10.1158/1078-0432.ccr-07-5136",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2008,
        9,
        2
      ]
    ],
    "date-time": "2008-09-02T14:59:51Z",
    "timestamp": 1220367591000
  },
  "page": "5318-5324",
  "update-policy": "http://dx.doi.org/10.1158/crossmark_policy",
  "source": "Crossref",
  "is-referenced-by-count": 274,
  "title": "Targeting the MDM2-p53 Interaction for Cancer Therapy",
  "prefix": "10.1158",
  "volume": "14",
  "author": [
    {
      "given": "Sanjeev",
      "family": "Shangary",
      "sequence": "first",
      "affiliation": [
        {
          "name": "1Comprehensive Cancer Center and Departments of"
        },
        {
          "name": "2Internal Medicine,"
        }
      ]
    },
    {
      "given": "Shaomeng",
      "family": "Wang",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "1Comprehensive Cancer Center and Departments of"
        },
        {
          "name": "2Internal Medicine,"
        },
        {
          "name": "3Pharmacology, and"
        },
        {
          "name": "4Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan"
        }
      ]
    }
  ],
  "member": "1086",
  "published-online": {
    "date-parts": [
      [
        2008,
        9,
        2
      ]
    ]
  },
  "reference": [
    {
      "key": "2022061021500188700_B1",
      "doi-asserted-by": "crossref",
      "unstructured": "Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med\u20082007;85:1175\u201386.",
      "DOI": "10.1007/s00109-007-0221-2"
    },
    {
      "key": "2022061021500188700_B2",
      "doi-asserted-by": "crossref",
      "unstructured": "Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene\u20082003;22:9030\u201340.",
      "DOI": "10.1038/sj.onc.1207116"
    },
    {
      "key": "2022061021500188700_B3",
      "doi-asserted-by": "crossref",
      "unstructured": "Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer\u20082002;2:594\u2013604.",
      "DOI": "10.1038/nrc864"
    },
    {
      "key": "2022061021500188700_B4",
      "doi-asserted-by": "crossref",
      "unstructured": "Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature\u20081979;278:261\u20133.",
      "DOI": "10.1038/278261a0"
    },
    {
      "key": "2022061021500188700_B5",
      "doi-asserted-by": "crossref",
      "unstructured": "DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A\u20081979;76:2420\u20134.",
      "DOI": "10.1073/pnas.76.5.2420"
    },
    {
      "key": "2022061021500188700_B6",
      "doi-asserted-by": "crossref",
      "unstructured": "Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell\u20081979;17:43\u201352.",
      "DOI": "10.1016/0092-8674(79)90293-9"
    },
    {
      "key": "2022061021500188700_B7",
      "doi-asserted-by": "crossref",
      "unstructured": "Oren M, Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci U S A\u20081983;80:56\u20139.",
      "DOI": "10.1073/pnas.80.1.56"
    },
    {
      "key": "2022061021500188700_B8",
      "doi-asserted-by": "crossref",
      "unstructured": "Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell\u20081989;57:1083\u201393.",
      "DOI": "10.1016/0092-8674(89)90045-7"
    },
    {
      "key": "2022061021500188700_B9",
      "doi-asserted-by": "crossref",
      "unstructured": "Koshland DE, Jr. Molecule of the year. Science\u20081993;262:1953.",
      "DOI": "10.1126/science.8266084"
    },
    {
      "key": "2022061021500188700_B10",
      "doi-asserted-by": "crossref",
      "unstructured": "Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol\u20082004;52:103\u201316.",
      "DOI": "10.1016/j.critrevonc.2004.07.002"
    },
    {
      "key": "2022061021500188700_B11",
      "doi-asserted-by": "crossref",
      "unstructured": "Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J\u20081991;10:1565\u20139.",
      "DOI": "10.1002/j.1460-2075.1991.tb07676.x"
    },
    {
      "key": "2022061021500188700_B12",
      "doi-asserted-by": "crossref",
      "unstructured": "Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature\u20081992;358:80\u20133.",
      "DOI": "10.1038/358080a0"
    },
    {
      "key": "2022061021500188700_B13",
      "doi-asserted-by": "crossref",
      "unstructured": "Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res\u20081998;26:3453\u20139.",
      "DOI": "10.1093/nar/26.15.3453"
    },
    {
      "key": "2022061021500188700_B14",
      "doi-asserted-by": "crossref",
      "unstructured": "Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell\u20081992;69:1237\u201345.",
      "DOI": "10.1016/0092-8674(92)90644-R"
    },
    {
      "key": "2022061021500188700_B15",
      "doi-asserted-by": "crossref",
      "unstructured": "Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev\u20081993;7:1126\u201332.",
      "DOI": "10.1101/gad.7.7a.1126"
    },
    {
      "key": "2022061021500188700_B16",
      "doi-asserted-by": "crossref",
      "unstructured": "Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol\u20081993;13:4107\u201314.",
      "DOI": "10.1128/MCB.13.7.4107"
    },
    {
      "key": "2022061021500188700_B17",
      "doi-asserted-by": "crossref",
      "unstructured": "Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol\u20081998;18:7288\u201393.",
      "DOI": "10.1128/MCB.18.12.7288"
    },
    {
      "key": "2022061021500188700_B18",
      "doi-asserted-by": "crossref",
      "unstructured": "Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature\u20081997;387:296\u20139.",
      "DOI": "10.1038/387296a0"
    },
    {
      "key": "2022061021500188700_B19",
      "doi-asserted-by": "crossref",
      "unstructured": "Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature\u20081995;378:206\u20138.",
      "DOI": "10.1038/378206a0"
    },
    {
      "key": "2022061021500188700_B20",
      "doi-asserted-by": "crossref",
      "unstructured": "Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature\u20081995;378:203\u20136.",
      "DOI": "10.1038/378203a0"
    },
    {
      "key": "2022061021500188700_B21",
      "unstructured": "Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene\u20081994;9:2523\u20139."
    },
    {
      "key": "2022061021500188700_B22",
      "doi-asserted-by": "crossref",
      "unstructured": "Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science\u20081996;274:948\u201353.",
      "DOI": "10.1126/science.274.5289.948"
    },
    {
      "key": "2022061021500188700_B23",
      "doi-asserted-by": "crossref",
      "unstructured": "Kastan MB. Wild-type p53: tumors can't stand it. Cell\u20082007;128:837\u201340.",
      "DOI": "10.1016/j.cell.2007.02.022"
    },
    {
      "key": "2022061021500188700_B24",
      "doi-asserted-by": "crossref",
      "unstructured": "Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med\u20082007;13:23\u201331.",
      "DOI": "10.1016/j.molmed.2006.11.002"
    },
    {
      "key": "2022061021500188700_B25",
      "doi-asserted-by": "crossref",
      "unstructured": "Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ\u20082006;13:921\u20136.",
      "DOI": "10.1038/sj.cdd.4401921"
    },
    {
      "key": "2022061021500188700_B26",
      "doi-asserted-by": "crossref",
      "unstructured": "Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science\u20082004;303:844\u20138.",
      "DOI": "10.1126/science.1092472"
    },
    {
      "key": "2022061021500188700_B27",
      "doi-asserted-by": "crossref",
      "unstructured": "Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A\u20082006;103:1888\u201393.",
      "DOI": "10.1073/pnas.0507493103"
    },
    {
      "key": "2022061021500188700_B28",
      "doi-asserted-by": "crossref",
      "unstructured": "Sarek G, Kurki S, Enback J, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest\u20082007;117:1019\u201328.",
      "DOI": "10.1172/JCI30945"
    },
    {
      "key": "2022061021500188700_B29",
      "doi-asserted-by": "crossref",
      "unstructured": "Koblish HK, Zhao S, Franks CF, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther\u20082006;5:160\u20139.",
      "DOI": "10.1158/1535-7163.MCT-05-0199"
    },
    {
      "key": "2022061021500188700_B30",
      "doi-asserted-by": "crossref",
      "unstructured": "Grasberger BL, Lu T, Schubert C, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem\u20082005;48:909\u201312.",
      "DOI": "10.1021/jm049137g"
    },
    {
      "key": "2022061021500188700_B31",
      "doi-asserted-by": "crossref",
      "unstructured": "Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc\u20082005;127:10130\u20131.",
      "DOI": "10.1021/ja051147z"
    },
    {
      "key": "2022061021500188700_B32",
      "doi-asserted-by": "crossref",
      "unstructured": "Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2\u201353 interaction. J Med Chem\u20082006;49:3432\u20135.",
      "DOI": "10.1021/jm051122a"
    },
    {
      "key": "2022061021500188700_B33",
      "doi-asserted-by": "crossref",
      "unstructured": "Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A\u20082008;105:3933\u20138.",
      "DOI": "10.1073/pnas.0708917105"
    },
    {
      "key": "2022061021500188700_B34",
      "doi-asserted-by": "crossref",
      "unstructured": "Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem\u20082006;281:33030\u20135.",
      "DOI": "10.1074/jbc.C600147200"
    },
    {
      "key": "2022061021500188700_B35",
      "doi-asserted-by": "crossref",
      "unstructured": "Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res\u20082006;66:3169\u201376.",
      "DOI": "10.1158/0008-5472.CAN-05-3832"
    },
    {
      "key": "2022061021500188700_B36",
      "doi-asserted-by": "crossref",
      "unstructured": "Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem\u20082006;281:33036\u201344.",
      "DOI": "10.1074/jbc.M605405200"
    },
    {
      "key": "2022061021500188700_B37",
      "doi-asserted-by": "crossref",
      "unstructured": "Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature\u20082006;444:61\u20136.",
      "DOI": "10.1038/nature05194"
    },
    {
      "key": "2022061021500188700_B38",
      "doi-asserted-by": "crossref",
      "unstructured": "Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem\u20082004;279:53015\u201322.",
      "DOI": "10.1074/jbc.M410233200"
    },
    {
      "key": "2022061021500188700_B39",
      "doi-asserted-by": "crossref",
      "unstructured": "Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem\u20082001;268:2784\u201391.",
      "DOI": "10.1046/j.1432-1327.2001.02228.x"
    },
    {
      "key": "2022061021500188700_B40",
      "doi-asserted-by": "crossref",
      "unstructured": "Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin. Cancer Res\u20082007;67:7350\u20137.",
      "DOI": "10.1158/0008-5472.CAN-07-0200"
    },
    {
      "key": "2022061021500188700_B41",
      "doi-asserted-by": "crossref",
      "unstructured": "Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature\u20081993;362:847\u20139.",
      "DOI": "10.1038/362847a0"
    },
    {
      "key": "2022061021500188700_B42",
      "doi-asserted-by": "crossref",
      "unstructured": "Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells\u20081997;15:82\u201393.",
      "DOI": "10.1002/stem.150082"
    },
    {
      "key": "2022061021500188700_B43",
      "doi-asserted-by": "crossref",
      "unstructured": "Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell\u20082006;10:501\u201314.",
      "DOI": "10.1016/j.ccr.2006.10.010"
    },
    {
      "key": "2022061021500188700_B44",
      "doi-asserted-by": "crossref",
      "unstructured": "Bottger V, Bottger A, Garcia-Echeverria C, et al. Comparative study of the p53\u2013mdm2 and p53-MDMX interfaces. Oncogene\u20081999;18:189\u201399.",
      "DOI": "10.1038/sj.onc.1202281"
    },
    {
      "key": "2022061021500188700_B45",
      "doi-asserted-by": "crossref",
      "unstructured": "Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem\u20082003;278:45946\u201353.",
      "DOI": "10.1074/jbc.M308295200"
    },
    {
      "key": "2022061021500188700_B46",
      "doi-asserted-by": "crossref",
      "unstructured": "Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73\u20132 binding and enhances p73 function. Oncogene\u20082008;27:997\u20131003.",
      "DOI": "10.1038/sj.onc.1210707"
    },
    {
      "key": "2022061021500188700_B47",
      "doi-asserted-by": "crossref",
      "unstructured": "Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene\u20082007;26:3473\u201381.",
      "DOI": "10.1038/sj.onc.1210136"
    },
    {
      "key": "2022061021500188700_B48",
      "doi-asserted-by": "crossref",
      "unstructured": "LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1\u03b1 and Hdm2. Cancer Res\u20082007;67:450\u20134.",
      "DOI": "10.1158/0008-5472.CAN-06-2710"
    },
    {
      "key": "2022061021500188700_B49",
      "doi-asserted-by": "crossref",
      "unstructured": "Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor activity. Nature\u20082008;451:76\u201380.",
      "DOI": "10.1038/nature06412"
    },
    {
      "key": "2022061021500188700_B50",
      "doi-asserted-by": "crossref",
      "unstructured": "Secchiero P, Corallini F, Gonelli A, et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res\u20082007;100:61\u20139.",
      "DOI": "10.1161/01.RES.0000253975.76198.ff"
    },
    {
      "key": "2022061021500188700_B51",
      "doi-asserted-by": "crossref",
      "unstructured": "Binder BR. A novel application for murine double minute 2 antagonists: the p53 tumor suppressor network also controls angiogenesis. Circ Res\u20082007;100:13\u20134.",
      "DOI": "10.1161/01.RES.0000255897.84337.38"
    },
    {
      "key": "2022061021500188700_B52",
      "doi-asserted-by": "crossref",
      "unstructured": "Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1\u03b1. Genes Dev\u20082000;14:34\u201344.",
      "DOI": "10.1101/gad.14.1.34"
    },
    {
      "key": "2022061021500188700_B53",
      "doi-asserted-by": "crossref",
      "unstructured": "Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res\u20082005;65:1918\u201324.",
      "DOI": "10.1158/0008-5472.CAN-04-3576"
    },
    {
      "key": "2022061021500188700_B54",
      "doi-asserted-by": "crossref",
      "unstructured": "Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood\u20082006;108:993\u20131000.",
      "DOI": "10.1182/blood-2005-12-5148"
    },
    {
      "key": "2022061021500188700_B55",
      "doi-asserted-by": "crossref",
      "unstructured": "Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies P53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood\u20082007;111:1584\u201393.",
      "DOI": "10.1182/blood-2007-09-112698"
    },
    {
      "key": "2022061021500188700_B56",
      "doi-asserted-by": "crossref",
      "unstructured": "Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood\u20082005;106:3150\u20139.",
      "DOI": "10.1182/blood-2005-02-0553"
    },
    {
      "key": "2022061021500188700_B57",
      "doi-asserted-by": "crossref",
      "unstructured": "Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53\u20132 binding inhibitors by facilitating MDMX degradation. Cell Cycle\u20082008;7:1604\u201312.",
      "DOI": "10.4161/cc.7.11.5929"
    },
    {
      "key": "2022061021500188700_B58",
      "doi-asserted-by": "crossref",
      "unstructured": "Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell\u20082004;119:591\u2013602.",
      "DOI": "10.1016/j.cell.2004.11.022"
    },
    {
      "key": "2022061021500188700_B59",
      "doi-asserted-by": "crossref",
      "unstructured": "Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene\u20082007;26:1317\u201323.",
      "DOI": "10.1038/sj.onc.1210199"
    },
    {
      "key": "2022061021500188700_B60",
      "doi-asserted-by": "crossref",
      "unstructured": "Cattelani S, Defferrari R, Marsilio S, et al. Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients. Clin Cancer Res\u20082008;14:3248\u201353.",
      "DOI": "10.1158/1078-0432.CCR-07-4725"
    },
    {
      "key": "2022061021500188700_B61",
      "doi-asserted-by": "crossref",
      "unstructured": "Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets\u20082005;5:27\u201341.",
      "DOI": "10.2174/1568009053332636"
    },
    {
      "key": "2022061021500188700_B62",
      "doi-asserted-by": "crossref",
      "unstructured": "Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood\u20082006;107:4122\u20139.",
      "DOI": "10.1182/blood-2005-11-4465"
    },
    {
      "key": "2022061021500188700_B63",
      "doi-asserted-by": "crossref",
      "unstructured": "Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood\u20082006;107:4109\u201314.",
      "DOI": "10.1182/blood-2005-08-3273"
    },
    {
      "key": "2022061021500188700_B64",
      "doi-asserted-by": "crossref",
      "unstructured": "Secchiero P, Zerbinati C, di Iasio MG, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab\u20082007;8:395\u2013403.",
      "DOI": "10.2174/138920007780655432"
    },
    {
      "key": "2022061021500188700_B65",
      "doi-asserted-by": "crossref",
      "unstructured": "Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res\u20082007;13:3380\u20137.",
      "DOI": "10.1158/1078-0432.CCR-06-2581"
    },
    {
      "key": "2022061021500188700_B66",
      "doi-asserted-by": "crossref",
      "unstructured": "Kranz D, Dobbelstein M. Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res\u20082006;66:10274\u201380.",
      "DOI": "10.1158/0008-5472.CAN-06-1527"
    },
    {
      "key": "2022061021500188700_B67",
      "unstructured": "Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther\u20082003;2:1023\u20139."
    },
    {
      "key": "2022061021500188700_B68",
      "doi-asserted-by": "crossref",
      "unstructured": "Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell\u20082006;127:1323\u201334.",
      "DOI": "10.1016/j.cell.2006.12.007"
    }
  ],
  "container-title": "Clinical Cancer Research",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://aacrjournals.org/clincancerres/article-pdf/14/17/5318/1976660/5318.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "syndication"
    },
    {
      "URL": "https://aacrjournals.org/clincancerres/article-pdf/14/17/5318/1976660/5318.pdf",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        6,
        11
      ]
    ],
    "date-time": "2022-06-11T03:08:50Z",
    "timestamp": 1654916930000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://aacrjournals.org/clincancerres/article/14/17/5318/72905/Targeting-the-MDM2-p53-Interaction-for-Cancer"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  },
  "references-count": 68,
  "journal-issue": {
    "issue": "17",
    "published-online": {
      "date-parts": [
        [
          2008,
          9,
          2
        ]
      ]
    },
    "published-print": {
      "date-parts": [
        [
          2008,
          9,
          1
        ]
      ]
    }
  },
  "URL": "http://dx.doi.org/10.1158/1078-0432.CCR-07-5136",
  "relation": {},
  "ISSN": [
    "1078-0432",
    "1557-3265"
  ],
  "subject": [],
  "published": {
    "date-parts": [
      [
        2008,
        9,
        1
      ]
    ]
  }
}